Bone tissue as a systemic endocrine regulator

• Published in: Physiological research Vol. 64; no. 4; pp. 439 - 445
• Main Author: Zofkova, I
• Format: Journal Article
• Language: English
• Published: Czech Republic Institute of Physiology 01.01.2015
• Subjects: Angiotensins - metabolism; Animals; Bone and Bones - metabolism; Bone Morphogenetic Proteins - metabolism; Cytokines; Diabetes; Endocrine System - metabolism; Enzymes; Growth factors; Homeostasis; Hormones; Hormones - metabolism; Humans; Hypertension; Incretins - metabolism; Infertility; Kinases; Metabolism; Models, Biological; Osteocalcin - metabolism; Osteoporosis; Pharmaceuticals
• ISSN: 0862-8408; 1802-9973
• DOI: 10.33549/physiolres.932900

Bone is a target tissue for hormones, such as the sex steroids, parathormon, vitamin D, calcitonin, glucocorticoids, and thyroid hormones. In the last decade, other "non-classic" hormones that modulate the bone tissue have been identified. While incretins (GIP and GLP-1) inhibit bone remodeling, angiotensin acts to promote remodeling. Bone morphogenetic protein (BMP) has also been found to have anabolic effects on the skeleton by activating bone formation during embryonic development, as well as in the postnatal period of life. Bone has also been identified as an endocrine tissue that produces a number of hormones, that bind to and modulate extra-skeletal receptors. Osteocalcin occupies a central position in this context. It can increase insulin secretion, insulin sensitivity and regulate metabolism of fatty acids. Moreover, osteocalcin also influences phosphate metabolism via osteocyte-derived FGF23 (which targets the kidneys and parathyroid glands to control phosphate reabsorption and metabolism of vitamin D). Finally, osteocalcin stimulates testosterone synthesis in Leydig cells and thus may play some role in male fertility. Further studies are necessary to confirm clinically important roles for skeletal tissue in systemic regulations.